Abstract: Composition and methods that include potassium nitrate for whitening and/or reducing tooth sensitivity. The dental compositions may optionally include a dental bleaching agent, such as hydrogen peroxide or carbamide peroxide. The dental compositions may be applied directly to the person's teeth, or they may be loaded into a comfortable fitting, flexible, thin-walled dental tray and placed over the person's teeth. In that case, the dental compositions will include a tackifying agent, such as carboxypolymethylene, dispersed within a solvent, which assists the composition in retaining the dental tray over the person's teeth as a result of the adhesive properties of the dental composition rather than due to mechanical interlocking of the tray over the person's teeth. The dental compositions may further include anticariogenic and antimicrobial agents.

Abstract: The present invention is directed to alkyl allyl amine monomers and their use as a polymerizate in a low VOC hair spray formulation. The hair spray formulation preferably includes a polymerizate of an alkyl allyl amine monomer, preferably an alkyl diallyl amine monomer alone or in combination with other known monomers. The hair spray formulation preferentially satisfies low VOC requirements while maintaining characteristics desired in a hair fixative product.

Abstract: A medicinal aerosol formulation including 0.01-5% medicament, at least 50% by weight 1,1,1,2-tetrafluoroethane (134a), less than 5% surface active agent, and at least one compound having higher polarity than 1,1,1,2-tetrafluoroethane, and which is free of chlorofluorocarbons and propellants CHClF2, CH2F2 and CF3CH3.

Abstract: The invention is of a topical medicament and associated methodology for use thereof, through the use of which fibrotic or connective tissue disorders involving scarring, sub-dermal plaque accumulations or fibrosis of muscle tissue may be effectively, cost effectively, and painlessly treated. One or more calcium channel blocker agents serve as the primary active ingredient of the present compositions, with carrier agents facilitating non-invasive transdermal delivery of the calcium channel blocker(s) to subdermal disease sites.

Abstract: An improved porous ceramic body to be embedded in a patient for sustained release of a medicament, and a method of making the ceramic body is provided. To control the release of the medicament, the pores of the ceramic body decrease in diameter from the inner surface to the outer surface of the body whereby the pore diameter is substantially proportional to the distance from the outer surface of the carrier. First, raw ceramic slurry is made from the blend of &bgr;-TCP, deflocculating agent, and water. Next, using a syringe the ceramic slurry is supplied to the internal region of a solvent-absorbable mold from an aperture along the inner wall surface. Then, the ceramic slurry is quickly dehydrated before thinly adhering itself onto the inner wall surface of the mold. Therefore, a preformed body having a hollow is obtained. Next, after fully being dried, the dried preformed body is fired at 1,050° C. for an hour before eventually yielding a spherical carrier for use in sustained release preparation.

Abstract: A solubilized cosmetic composition containing an ingredient which is difficult to be dissolved in water, an alkyl-modified carboxyvinyl polymer and a hydroxyalkylated cyclodextrin so as to solubilize the ingredient difficult to be dissolved in water and in particular substantially not containing a surfactant.

Abstract: A single-phase autophobic hairspray composition containing 0.5% to 10% by weight of a film-forming hairspray resin; 10% to 60% by weight of a binary mixed propellant system; 0.01% to 1.0% by weight of an autophobic silicone hairspray additive; and 10% to 25% by weight water, is described.

Abstract: A pharmaceutical composition solubilized in a propellant that can be administered buccally or to the lungs using a metered dose dispenser is provided. The composition comprises a pharmaceutical agent; glycerin and/or polyglycerin; phenol and/or methyl phenol; and at least one absorption enhancing compound. A pressurized container with the composition and a methods of making the composition are also provided.

Abstract: Hair spray compositions containing a carboxylated polyurethane resin, and having a low volatile organic content, are disclosed. The compositions have a low viscosity, and can be applied as a pump spray or as an aerosol, to hold the hair and impart excellent hair set retention properties. The hair spray compositions can be used with a curling iron or a blow dryer to style the hair.

Abstract: A cosmetic preparation is presented containing (a) alkyl or alkenyl oligoglycosides (b) polyol poly-12-hydroxystearates and (c) dihydroxyacetone. This self-tanning cosmetic preparation has high dermatological compatibility, a favorable feeling on the skin and good storage stability at relatively high temperatures.

Abstract: The small particle liposome or lipid complex aerosol compounds and methods of treatment of the present invention involve lipid- or water soluble anti-cancer drugs incorporated into liposomes or other lipid complexes. The liposomes and complexes are administered in aqueous dispersions from a jet nebulizer to the respiratory tract of an individual. Various anti-cancer drugs may be used, including 20-S-Camptothecin, 9-Nitro-camptothecin, 9-Amino-camptothecin, 10, 11-methylenedioxy-camptothecin and taxol or its derivatives. Administration of these drugs by inhalation provides faster and more efficient absorption of the anticancer drug than does intramuscular administration or oral administration.

Abstract: A clarified algae extract used to obtain a composition having antibacterial and/or antifungal activity, said extract being obtained according to a method comprising the stages of release of the intracellular content of the algae cells and clarification by filtration of said intracellular content, in order to obtain a clarified filtration permeate, said extract comprising a molecular fraction containing halogenated organic molecules having a molecular weight of more than 10,000.

Abstract: Pharmaceutical solution aerosol formulations comprising beclomethasone 17,21 dipropionate, ethanol, and a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, and a mixture thereof.

Abstract: The present invention is directed to low volatile organic compound aerosol hair cosmetic compositions which contain nonionically derivatized starches optionally hydrolyzed and/or ionically modified, about 5-55% propellant, up to 50% solvent, and water. Such compositions provide a clear solution with a low viscosity, good spray caracteristics, a clear, non-tacky film, good stiffness, and improved humidity resistance.

Abstract: The current invention is directed to methods of treating or preventing emphysema, pharmaceutical compositions suitable for the treatment or prevention of emphysema and methods for delivering formulations into the lung of a mammal suffering from emphysema. More generally, the invention encompasses the use of 13-cis-retinoic acid to treat or prevent certain chronic obstructive airway disorders, particularly chronic obstructive pulmonary disease including chronic bronchitis, emphysema and asthma in mammals, especially humans that smoke or smoked cigarettes. In another aspect, the present invention encompasses the use of pharmaceutical compositions of 13-cis-retinoic acid to treat emphysema. Moreover, the current invention encompasses the use of electrohydrodynamic aerosol devices, aerosol devices and nebulizers to deliver formulations of 13-cis-retinoic acid into the lung of a mammal suffering from emphysema. The invention also encompasses the systemic use as well as the local use of 13-cis-retinoic acid.

Abstract: To optimize the delivery of all-trans retinoic acid to lung tissue, the potential of vehiculating this drug in liposomes and delivering it via aerosol was determined. Liposomes provide a means to prevent local irritation of lung tissue, reduce pulmonary toxicity, prolong therapeutic levels, and generate high drug concentrations at the tumor sites. Therefore, the delivery of ATRA to the lung tissue in mice was accomplished by nebulization of L-ATRA. The liposomes in the aerosol were uniform, stable, and retained the drug well. The drug was effectively delivered at high concentrations to the lungs of mice and was retained at least up to 96 h after a single exposure to L-ATRA aerosols. The aerosol-delivered ATRA was biologically active as demonstrated by its ability to induce the expression of tissue-type transglutaminase. Aerosol delivery of L-ATRA offers an effective way to deliver high levels of ATRA to the lung without apparent pulmonary toxic effects.

Abstract: The present invention discloses a method for treating dental caries, comprising administering a composition comprising an effective amount of at least one lytic enzyme produced by a bacteriophage specific for said bacteria, the lytic enzyme having the ability to digest a cell wall of the bacteria infecting all or part of a mouth or teeth, and a carrier for delivering the enzyme to the mouth and teeth.

Abstract: A pharmaceutical aerosol formulation comprising (i) particulate medicament, (ii) 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3,-heptafluoro-n-propane or a mixture thereof as propellant, and (iii) 0.01 to 5% w/w based upon the propellant of a polar cosolvent, the particulate medicament being present in an amount from 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, and which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament.

Abstract: Cosmetic compositions for topical application to the skin are in the form of a water-in-oil emulsion and comprise (a) continuous oil phase comprising a mixture of volatile silicone and non-volatile silicone; (b) discontinuous aqueous phase; and (c) willow bark extract.

Abstract: A method of treating pneumonia caused by a microorganism by administering directly into the lower respiratory tract of a host an amount of an anti-inflammatory agent effective to reduce inflammation is provided. The method may further include administering to a host an amount of an anti-infectious agent with activity against the microorganism effective to reduce the concentration of the microorganism.